Combating liver cancer through GO-targeted biomaterials

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Hydroxycamptothecin (HCPT) is a topoisomerase I inhibitor used for cancer treatment.
• HCPT's clinical use is limited by poor water solubility and toxicity.
• Effective tumor-specific drug delivery is crucial for enhancing HCPT efficacy.

Purpose of the Study:

• To investigate the anti-proliferative and anti-migratory effects of HCPT on human liver cancer cells (HepG-2).
• To develop a novel drug delivery system using modified graphene oxide (GO) for targeted HCPT delivery.
• To evaluate the biocompatibility and drug-loading capacity of the developed nano-carrier system.

Main Methods:

• Human liver cancer cells (HepG-2) were treated with HCPT to assess its effects on proliferation and migration.
• Graphene oxide (GO) was modified with carboxymethyl chitosan (CMC) and hyaluronic acid (HA) to create a nano-carrier.
• The GO-CMC-HA/HCPT system was evaluated for its ability to deliver HCPT to HepG-2 cells and its therapeutic efficacy in vitro and in vivo.

Main Results:

• HCPT significantly inhibited HepG-2 cell proliferation and migration.
• The GO-CMC-HA nano-carrier system demonstrated good biocompatibility and high drug loading capacity.
• The GO-CMC-HA/HCPT system enhanced HCPT uptake by HepG-2 cells, leading to increased apoptosis and improved anti-cancer efficacy.

Conclusions:

• The developed GO-based drug delivery system shows promise for targeted therapy of liver tumors.
• This nano-carrier system improves HCPT's efficacy by enhancing cellular uptake and tumor accumulation.
• This study presents a potential therapeutic strategy for liver cancer using a novel nano-drug delivery system.